Hyalurom CS buy with delivery at wholesale prices in Moscow

Instructions for use Hyalurom cs synovial fluid prosthesis 3ml 1 pc.

Composition and release form

1 pre-filled syringe with Hyalur CS contains:

Sodium hyaluronate 60.00 mg
Chondroitin sulfate sodium 90.00 mg
Sodium chloride 10.50 mg
Excipients
Water for injections up to 3.00 ml

Hyalurom CS is a synovial fluid prosthesis, a sterile, transparent viscoelastic solution, which contains sodium hyaluronate 60 mg/3 ml and sodium chondroitin sulfate 90 mg/3 ml (registered in the Russian Federation on September 10, 2008, No. RU P N014581/01).

Hyaluronic acid is the main component of synovial fluid, determining its viscoelastic properties. It forms a covering layer on the entire inner surface of the joint that protects the cartilage and synovial membrane from mechanical damage, as well as from free radicals and inflammatory factors.

Chondroitin sulfate is one of the naturally occurring glycosaminoglycans (GAGs), consisting of the alternative sugar D-glucuronic acid and N-acetyl-Dgalactosamine.

Chondroitin sulfate is obtained in the form of sodium salt from the trachea of cattle and is used for the preparation of active pharmaceutical ingredients.

Chondroitin sulfate is a stimulator of tissue regeneration, promotes water retention and restoration of shock-absorbing functions in cartilage tissues.

Promotes the synthesis and protection of collagen, which is the structural basis of all connective tissues, and also increases the production of hyaluronic acid in synovial cells, which has a beneficial effect on maintaining the viscosity of synovial fluid.

The use of chondroitin sulfate together with sodium hyaluronate helps slow down degradation and stimulate cartilage regeneration.

Indications

Hyalur CS is used:

for the symptomatic treatment of mild, moderate or severe osteoarthritis;
for pain and limitation of mobility caused by degenerative-dystrophic or post-traumatic changes in the knee, hip and other synovial joints;
to relieve pain after arthroscopy (use is possible no earlier than 1 week after the intervention).

CONTRAINDICATIONS

established hypersensitivity to the components of this medical device;
the presence of active inflammatory or infectious processes in the joint;
presence of signs of active skin disease or skin infection in the area of the intended injection;
use in patients diagnosed with an autoimmune disease or undergoing immunotherapy;
use during pregnancy or lactation;
age up to 18 years.

Hyalurom solution for intra-articular injection 1.5% syringe 2ml No. 1

A country

Romania
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Compound

Syringe 2 ml
Sodium hyaluronate, sodium chloride, water for injection.

pharmachologic effect

Solution for intra-articular administration HYALUROM - 1.5% sodium hyaluronate solution in disposable 2 ml syringes is a sterile, viscoelastic solution of sodium hyaluronate. Sodium hyaluronate is obtained as a result of fermentation. Sodium hyaluronate HYALUROM is a polysaccharide identical to human, consisting of repeating disaccharide units of N-acetylglycosamine and sodium glucuronate, with a molecular weight exceeding 2,400,000 Da. Sodium hyaluronate is ubiquitous in the human body and is present in high concentrations in tissues such as the vitreous, synovial fluid, umbilical cord and dermis. In synovial fluid, sodium hyaluronate acts as a lubricant and shock absorber, promoting normal movement without pain. In a disease such as arthritis, the viscoelasticity of the synovial fluid decreases, so that the mechanical load on the joint significantly increases and the destruction of articular cartilage increases, manifested by limitation and pain when moving the joints. The lubricating and shock-absorbing effect of this drug alleviates pain and improves joint mobility when used intra-articularly. These effects continue for more than 6 months after one course of treatment.

Indications for use

HYALUROM solution is used as a viscoelastic additive to replace synovial fluid for pain caused by degenerative diseases of synovial joints, such as osteoarthritis or osteoarthritis.
In its action, the drug HYALUROM serves as a lubricant and mechanical support for the diseased joint. The HYALUROM solution is injected into human joints: - for pain and limited mobility caused by degenerative-dystrophic and traumatic changes in the knee, hip and other synovial joints; - for temporary replacement and replenishment of synovial fluid; - when treating patients who lead an active lifestyle and regularly load the affected joint.

Mode of application

HYALUR injections are performed by medical specialists. HYALUROM solution is intended for intra-articular use only. Do not use intravenously. Sodium hyaluronate is administered at room temperature. The volume injected depends on the size of the joint, but does not exceed 2 ml in the knee and other large joints, or 1 ml for small joints. The physician is responsible for establishing the applicable volume and must ensure that the joint is not overloaded. The HYALUROM solution is injected into the joint cavity once a week for 3 weeks in a row. It is possible to treat several joints simultaneously. A repeated cycle of treatment cannot be carried out earlier than after 6 months for the same joint. Before using the drug HYALUROM, fluid accumulations in the joint must be removed by suction with a syringe. HYALUROM solution is available in the form of a pre-filled syringe, the contents of which do not need to be diluted. The drug is sterile and should be used immediately after opening the package. The drug is intended for one-time use only. HYALUROM should be carefully introduced into the joint cavity, carefully following the injection schedule. Administration is an aseptic procedure, so take appropriate precautions. The finished syringe is removed from the sterile case, the cap is removed, after which a sterile needle is put on, which is fixed with a slight turn. Before administration, the air must be removed from the syringe.

Side effect

Sodium hyaluronate has excellent tolerability. It is possible that local secondary effects such as pain, a feeling of warmth, redness and swelling may occur in the joint into which the drug is injected (applying ice to the joint for five to ten minutes will relieve all such phenomena). Allergic reactions can occur extremely rarely. When administered intra-articularly, there are minimal risks associated with infection and bleeding.

Contraindications

— individual intolerance (including a history of hypersensitivity) to the components of the HYALUROM solution; - presence of infected wounds, abrasions in the joint area; - infectious diseases of the joints; - known systemic bleeding disorders. HYALUROM may contain traces of bacterial proteins and is contraindicated in patients with relevant hypersensitivity.

Dispensing conditions in pharmacies

On prescription

Application

Hyalurome CS is intended for intra-articular administration.

The solution should not be administered outside the joint cavity, or in patients with infections or skin diseases in the injection area.

Intra-articular injection should be administered by specialists trained in intra-articular injection techniques and performed under aseptic conditions in medical institutions.

It is possible to use local anesthetics before intra-articular injection, for example, subcutaneous administration of lidocaine.

It is necessary to properly disinfect the injection site (use a 70% alcohol solution or other disinfectants). Disinfectants containing quaternary ammonium salts (for example, benzalkonium chloride) should not be used, as a precipitation reaction may occur.

Before administering Hyaluroma CS, fluid should be removed from the joint cavity.

It is recommended to perform arthrocentesis before administering the solution.

After removing the protective cap from the syringe tip, attach a sterile needle to the syringe. Typically, for the knee joint, a needle measuring 0.8x40 mm (21G) is used; for other joints, we recommend using a needle of the required size (from 17G to 22G) depending on the joint.

Hyalurome CS is injected into the joint in a volume depending on the size of the joint. The joint cavity should not be overloaded.

Each pre-filled syringe is intended for single use. The contents of the syringe must be used immediately after opening. Unused solution cannot be stored and should not be re-sterilized.

After injection of Hyaluroma CS, the patient is advised to adhere to a gentle regimen and avoid excessive or prolonged stress on the joints (for example, running or playing tennis) for 48 hours.

Hyalurom tendon solution for peritendinous and intra-articular injection 40 mg/2 ml 2 ml 1 pc. syringe

Composition and release form Hyalurom tendon solution for peritendinous and intra-articular injection 40 mg/2 ml 2 ml 1 pc. syringe

Syringe - 2 ml:

Sodium hyaluronate С14Н20NNaO11 CAS [9067-32-7] 40.00 mg;
Pharmasal – Sodium chloride NaCl CAS [7647-14-5] 14.00 mg;
Sodium dihydrogen phosphate monohydrate NaH2PO4 x H2O CAS [10049-21-5] 0.11 mg;
Disodium phosphate dodecahydrate Na2HPO4 x 12H2O CAS [10039-32-4] 1.22 mg;
Mannitol (Perlitol PF) C6H14O6 CAS [69-65-8] 10.00 mg;
Sodium hydroxide NaOH CAS [1310-73-2], Hydrochloric acid HCl CAS [7647-01-0] to pH 7.2÷7.5%;
Water for injection H2O up to 2.00 ml.

Hyalurom Tendon is a sterile solution in pre-filled disposable glass syringes of hydrolytic class I, containing sodium hyaluronate 40 mg/2 ml.

1 pre-filled syringe in a plastic cell packaging along with instructions for use in a cardboard box.

Description of the dosage form

Hyalurom Tendon is a sterile, viscoelastic, transparent, colorless solution of highly purified sodium hyaluronate. Sodium hyaluronate is obtained by bacterial fermentation and does not contain animal protein. Sterilized with wet steam.

Hyalurom Tendon is intended for peritendinous and intra-articular administration.

Characteristic

Hyalurom Tendon is a sterile, viscoelastic, clear, colorless solution of sodium hyaluronate, placed in a disposable, hydrolytic class I clear glass syringe, siliconized and equipped with an elastomeric cap, piston rod and flange for control.

There is no graduation of the syringe; it is not required, since the contents of one syringe are used once and are intended only for one patient.

Hyalurome Tendon has a dynamic viscosity in the range of 35-65 Pa∙s, osmolality is 270-350 mOsmol/kg, solution density is 1.005-1.025 g/cm3.

Field of application: surgery, traumatology, orthopedics, rheumatology.

Directions for use and doses

Hyalur Tendon should only be administered by physicians trained in the technique of insertion into the peritendinous space and the tendon insertion or into the joint cavity, and should be performed under aseptic conditions in medical institutions.

For peritendinous injection:

Hyalur Tendon is injected into the area of the affected tendon or into the site of tendon attachment once a week, the course is 2 injections. Several tendons can be treated at the same time. Repeated courses of treatment may be used as necessary.

For intra-articular administration:

Hyalur Tendon is injected into the affected joint once a week, the course is 1-3 injections. Several joints can be treated at the same time. The course of treatment can be repeated if necessary.

If joint effusion is present, it is recommended to reduce it by aspiration, followed by rest, ice packs, and/or intra-articular corticosteroid injection if necessary. Treatment with Hyalurom Tendon can begin after two to three days.

For peritendinous injection:

Take the syringe, unscrew the protective cap, attach a needle of a suitable size (for example, 25-27 G) and secure it with a slight rotation.

For intra-articular administration:

Take the syringe, unscrew the protective cap, attach a needle of a suitable size (for example, 18-25 G) and secure it with a slight rotation.

The final choice of needle for any procedure is determined by the attending physician. There are several factors that must be considered when selecting the size (gauge) and length of the needle to be used for peritendinous or intraarticular insertion, including the anatomy of the insertion site, the distance between the skin and the tendon, and patient characteristics (weight, age).

Before administration, air bubbles, if present, should be removed.

The contents of the Hyalurom Tendon syringe are sterile.

Indications for use Hyalur tendon solution for peritendinous and intra-articular injection 40 mg/2 ml 2 ml 1 pc. syringe

Pain and limitation of movement in various tendon diseases (chronic tendinopathies).

Pain and limitation of mobility due to primary or secondary osteoarthritis, post-traumatic changes or other joint diseases.

Contraindications

Hyalur Tendon should not be used:

patients with established hypersensitivity to any of its components;
patients with established hypersensitivity to proteins of gram-positive bacteria;
patients with signs of active skin disease or skin infection in the area of the intended injection;
patients who received another injectable drug in the area or in close proximity to the intended injection site;
in the presence of active inflammatory or infectious processes in the joint;
in the presence of systemic blood clotting disorders;
during pregnancy or lactation;
under the age of 18.

special instructions

Gialur Tendon should be used with caution to treat patients with known hypersensitivity to any of the components of the drug.

General precautions must be observed when injecting into the peritendinous space or into the joint cavity. Hyalurome Tendon should be inserted precisely into the peritendinous space or the area of the affected tendon, using diagnostic imaging, such as ultrasound or tomography, if necessary.

Avoid getting the needle into blood vessels and nerves!

Hyalurom Tendon is intended for peritendinous and intra-articular administration.

The procedure should be avoided in patients with known systemic bleeding disorders or in patients with a vasovagal reaction and a history of syncope.

It is not recommended to use Hyalurom Tendon in children, pregnant and lactating women due to insufficient data on the clinical use of sodium hyaluronate in these groups of patients.

Patients who experience any complications within a few days after the injection should contact their doctor immediately.

It is necessary to properly disinfect the injection site (use a 70% alcohol solution or other disinfectants). Disinfectants containing quaternary ammonium salts should not be used, as a precipitation reaction may occur.

Before use, you must check the integrity of the packaging. Use of open and/or damaged sterile packaging is not permitted.

The syringe is for single use only and should be used immediately after opening the package.

Used needles and syringes with solution cannot be stored or re-sterilized and should not be reused.

Side effects Hyalurom tendon solution for peritendinous and intra-articular injection 40 mg/2 ml 2 ml 1 pc. syringe

After peritendinous injection of Hyalur Tendon solution, local reactions may occur, such as pain, a feeling of heat, bruising, redness or swelling.

Moderate pain and swelling may occur after intra-articular injection of sodium hyaluronate. There are minimal risks associated with the intra-articular injection procedure, mainly infection and bleeding.

Drug interactions

Currently, there is no information about the incompatibility of Hyalur Tendon with other drugs used to treat diseases of the tendons or joints.

Properties

Hyalurome CS is designed to replenish the volume and restore the viscosity of synovial fluid in the joints. Hyalurome CS dissolves in the synovial fluid, providing a beneficial effect. It undergoes local transformations in the joint cavity, normalizes the properties of synovial fluid, returning its lubricating and shock-absorbing functions. The highest concentrations of hyaluronic acid in studies were found in the synovial fluid and joint capsule, lower concentrations in the synovial membrane, ligaments and adjacent muscles, excretion is mainly carried out by the kidneys. A single injection is recommended and the effect lasts for at least 6 months. This therapy for osteoarthritis is generally accepted, safe and effective.

Hyalurome CS, when administered once, restores the lubricating and shock-absorbing properties of synovial fluid, has a pronounced and long-term analgesic effect and significantly reduces the limitation of joint mobility.

Sodium hyaluronate is obtained by bacterial fermentation.

There are no data on the incompatibility of use simultaneously with medications.

Hyalurome CS is a medical device.